Drug intelligence / Profile preview

CBS-Na

Development stage: Preclinical
Lead developer: Northeast Forestry University
Modality: Small Molecules

Overview

**CBS-Na** is the water-soluble sodium-salt form of CBS, an experimental curcumin-borneol prodrug synthesized through a succinate ester linkage. In cellular and collagen-induced arthritis rat studies, CBS-Na showed antioxidant and anti-inflammatory activity, with suppression of ERK and p38 phosphorylation, reduced c-Fos/AP-1 signaling, and lower expression of MMP9 and inflammatory cytokines including TNF-alpha, IL-6, and IL-1beta. It is a preclinical candidate investigated for rheumatoid arthritis and has not been identified as an approved or marketed medicine. ([frontiersin.org](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1775735/full))

Targets

MAPK3 (Mitogen-activated protein kinase 1)MMP9 (Matrix metalloproteinase-9)RK (Ribokinase)FOS (Activator Protein 1)

Beyond the preview

Go deeper on CBS-Na.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBS-Na.

Explore the full profile